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Abstract
The aim of this study is to determine if fluorescence-guided surgery (FGS) can eradicate
human fibrosarcoma growing in the retroperitoneum of nude mice. One week after retroperito-
neal implantation of human HT1080 fibrosarcoma cells, expressing green fluorescent protein
(GFP) (HT-1080-GFP), in nudemice, bright-light surgery (BLS) was performed on all tumor-
bearing mice (n = 22). After BLS, mice were randomized into 2 treatment groups; BLS-only
(n = 11) or the combination of BLS + FGS (n = 11). The residual tumors remaining after BLS
were resected with FGS using a hand-held portable imaging system under fluorescence navi-
gation. The average residual tumor area after BLS + FGS was significantly smaller than after
BLS-only (0.4 ± 0.4 mm2 and 10.5 ± 2.4 mm2, respectively; p = 0.006). Five weeks after sur-
gery, the fluorescent-tumor areas of BLS- and BLS + FGS-treatedmice were 379 ± 147 mm2
and 11.7 ± 6.9 mm2, respectively, indicating that FGS greatly inhibited tumor recurrence com-
pared to BLS. The combination of BLS + FGS significantly decreased fibrosarcoma recur-
rence compared to BLS-only treated mice (p< 0.001). Mice treated with BLS+FGS had a
significantly higher disease-free survival rate than mice treated with BLS-only at five weeks
after surgery. These results suggest that combination of BLS + FGS significantly reduced the
residual fibrosarcoma volume after BLS and improved disease-free survival.
Introduction
Most tumors in the retroperitoneum are malignant, and about one third of these are soft tissue
sarcomas [1, 2]. Retroperitoneal tumors present several therapeutic challenges because of their
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relative late presentation and anatomical location [3]. Complete tumor resection can potential-
ly be a curative treatment modality for retroperitoneal soft tissue sarcoma patients [4], but
local recurrence occurs in a large proportion of patients and is responsible for as many as 75%
of sarcoma-related deaths [5].
Local recurrence often occurs following attempted curative resection of the primary tumor,
because all cancer cells are not removed by the surgeon due to the inability to see them. Making
tumors fluorescence offers great advantages for fluorescence-guided surgery (FGS) to achieve
complete resection [6].
Our laboratory has developed FGS of cancer using both fluorescent-protein labeling of the
tumor [7–16] as well as fluorescent-antibody labeling of the tumor [17–29], in orthotopic nude
mouse models of human tumors, including patient-derived orthotopic (PDOX) models [24,
25, 30].
In the present study, we report the effectiveness of using FGS to improve outcomes in a
retroperitoneal-implanted nude-mouse model of human fibrosarcoma, including reducing re-
sidual tumor tissue, thereby decreasing tumor recurrence and increasing disease-free survival.
Materials and Methods
Ethics Statement
All animal studies were conducted with an AntiCancer Institutional Animal Care and Use Com-
mittee (IACUC)-protocol specifically approved for this study and in accordance with the princi-
pals and procedures outlined in the National Institute of Health Guide for the Care and Use of
Animals under Assurance Number A3873-1. In order to minimize any suffering of the animals
the use of anesthesia and analgesics were used for all surgical experiments. Animals were anesthe-
tized with a 20 μL mixture of ketamine (20 mg/kg), acepromazine (0.48 mg/kg), and xylazine
(15.2 mg/kg) by intramuscular injection 10 minutes before surgery. The response of animals dur-
ing surgery was monitored to ensure adequate depth of anesthesia. Ibuprofen (7.5 mg/kg orally
in drinking water every 24 hours for 7 days post-surgery) was used in order to provide analgesia
post-operatively in the surgically-treated animals. The animals were observed on a daily basis
and humanely sacrificed by CO2 inhalation when they met the following humane endpoint crite-
ria: prostration, skin lesions, significant body weight loss, difficulty breathing, epistaxis, rotational
motion and body temperature drop. The use of animals was necessary to understand the in vivo
efficacy, in particular, anti-metastatic efficacy of the procedures tested. Animals were housed
with no more than 5 per cage. Animals were housed in a barrier facility on a high efficiency par-
ticulate air (HEPA)-filtered rack under standard conditions of 12-hour light/dark cycles. The ani-
mals were fed an autoclaved laboratory rodent diet (S1 ARRIVE Checklist).
Establishment of a green fluorescent protein labeled HT-1080
fibrosarcoma cell line
For green fluorescent protein (GFP) gene transduction of human HT-1080 fibrosarcoma cells
[31, 32], 80% confluent cells were used. Briefly, cells were incubated with a 1:1 precipitated
mixture of retroviral supernatants, of packaging PT67-GFP cells [33–35], which express the
GFP gene linked to the G418 resistance gene (Clontech, Mountain View, CA) and RPMI 1640
medium (Cellgro, Herndon, VA, USA) containing 10% fetal bovine serum (FBS) (Omega Sci-
entific, San Diego, CA, USA) for 72 h. Fresh medium was replenished at this time. Cells were
harvested with trypsin/EDTA 72 h post-transduction and subcultured at a ratio of 1:15 into
medium, which contained 200 μg/ml of the selective agent G418. The level of G418 was in-
creased stepwise up to 800 μg/ml [33–35].
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Cell culture
HT1080-GFP cells were maintained in RPMI 1640 medium supplemented with 10% FBS and
1% penicillin/streptomycin. The cells were incubated at 37°C in a humidified atmosphere of
5% CO2 in air and harvested by trypcinization at 80% confluence.
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA) were used in this study. Mice
were kept in a barrier facility under HEPA filtration. Mice were fed with an autoclaved labora-
tory rodent diet. All mouse surgical procedures and imaging were performed with the animals
anesthetized by subcutaneous injection of the ketamine mixture described above (20 μl).
All animal studies were conducted with an AntiCancer Institutional Animal Care and Use
Committee (IACUC)-protocol specifically approved for this study and in accordance with the
principals and procedures outlined in the National Institute of Health Guide for the Care and
Use of Animals under Assurance Number A3873-1.
Retroperitoneal implantation of HT1080-GFP cells
Four-week-old female nude mice were anesthetized by the ketamine mixture via s.c. injection.
The back was sterilized with alcohol. An approximately 1 cm skin incision was made just to the
right side of spine in order to expose the retroperitoneum. HT1080-GFP cells (1×106) in Matrigel
(5 μl) (BD Bioscience, San Jose, CA) per mouse were injected into the retroperitoneum with a
0.5 ml 28 G latex-free insulin syringe (TYCOHealth Group LP, Mansfield, MA). The skin was
closed with a 6-0 suture.
Fluorescence imaging
The Olympus OV100 Small Animal Imaging System (Olympus Corp., Tokyo, Japan), contain-
ing an MT-20 light source (Olympus Biosystems, Planegg, Germany) and DP70 CCD camera
(Olympus Corp., Tokyo, Japan) [36]; the Dino-Lite imaging system (AM4113T-GFBW Dino-
Lite Premier; AnMo Electronics Corporation, Taiwan) [30]; and the MVX10 long-working dis-
tance microscope (Olympus Corp.) [37] were used for imaging live mice. To analyze for recur-
rence and to follow tumor progression postoperatively, weekly noninvasive whole-body
imaging of the mice was performed using the iBox Scientia Small Animal Imaging System
(UVP LLC, Upland, CA, USA). GFP fluorescent-tumor areas were recorded every week [16,
38–40]. The working-distance setting for GFP imaging in the iBox was adjusted to image the
maximum possible fluorescent area in each mouse both before surgery and after surgery. All
images were analyzed with ImageJ v1.440 (National Institutes of Health).
Tumor resection
One week after retroperitoneal implantation of HT1080-GFP cells, bright-light surgery (BLS)
was performed to all tumor-bearing mice (n = 22). The exposed retroperitoneal tumor was im-
aged preoperatively with the OV100 at a magnification of 0.14×. Resection of the primary tumor
was performed under standard bright-field using the MVX10 microscope [37]. For fibrosarcoma
resection, intralesional and marginal tumor excision was performed in all the mice. Postopera-
tively, the surgical resection bed was imaged with the OV100 at a magnification of 0.14× or 0.56×
to detect residual tumor. The mice which underwent BLS were randomized into 2 treatment
groups: BLS only (n = 11) and BLS + FGS (n = 11) (Fig. 1). The residual tumors of the BLS +
FGS group of mice were resected using the Dino-Lite imaging system under fluorescence naviga-
tion. After completion of FGS, the surgical resection bed was imaged with the OV100 at a
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magnification of 0.14× or 0.89× to detect microscopic minimal residual cancer (MRC) [41]. The
incision was closed in one layer using 6-0 nylon surgical sutures after treatment.
Statistical analysis
Statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical Universi-
ty). Residual tumor area is expressed as mean ± SD. The two-tailed Student’s t-test was used to
compare continuous variables between 2 groups. Kaplan-Meier survival curves were used for
demonstrating mouse survival. Survival outcomes were compared using log rank tests. A p
value< 0.05 was considered statistically significant.
Results and Discussion
Efficacy of bright-light and bright-light plus fluorescence-guided surgery
Retroperitoneal mouse models of HT-1080-GFP human fibrosarcoma were established in
22 mice (Fig. 2A). One week after retroperitoneal implantation, the mice were randomly divid-
ed into the BLS or BLS + FGS groups (11 mice in each group) (Fig. 1). Before surgical resection,
the fluorescent-tumor areas of the mice in the BLS and BLS + FGS groups were 41.3 ± 15.4
mm2 and 47.9 ± 30.6 mm2, respectively (Fig. 2B). There was no significant difference in pre-
operative tumor burden between BLS and BLS + FGS mice. A great improvement in visualiza-
tion of the primary fibrosarcoma during FGS enhanced distinction of tumor from surrounding
soft tissues and identified a larger extent of tumor growth due to GFP expression by the tumor
(Fig. 3A). FGS following BLS resulted in a more complete resection of the fibrosarcoma,
Figure 1. Schematic diagram of the experimental protocol.One week after retroperitoneal fibrosarcoma implantation in 22 mice, the tumor-bearing mice
were randomly assigned to either the BLS-only or BLS + FGS groups. Resection of the tumor was performed using the Dino-Lite imaging system under
fluorescence navigation (14). Postoperatively, the surgical resection bed was imaged with the OV100 at a magnification of 0.14× or 0.56× to detect residual
fibrosarcoma cells.
doi:10.1371/journal.pone.0116865.g001
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Figure 2. Pre-operative images of retroperitoneal fibrosarcomamousemodel. A. Retroperitoneal fibrosarcomamouse model. B. Fluorescent-tumor
areas before surgery. There was no significant difference in fluorescent-tumor areas between the BLS-only and BLS + FGSmouse groups. The fluorescent
areas of tumors are expressed mean ± SD. All residual tumors expressing GFP were imaged with the Olympus OV100 Small Animal Imaging System
(Olympus Corp.) [36] and analyzed with ImageJ v1.440 (National Institutes of Health). Statistical analysis was performed using the Student’s t-test.
doi:10.1371/journal.pone.0116865.g002
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demonstrated by a significant decrease in the fluorescent area of the residual tumor compared
to BLS-only. Fluorescent areas of the residual tumors after BLS and the combination of BLS +
FGS were 10.5 ± 2.4 mm2 and 0.4 ± 0.4 mm2, respectively (Fig. 3B; p = 0.00597).
Time-course imaging of recurrent tumor growth after BLS or the
combination of BLS + FGS
Time-lapse imaging visualized rapid growth of the fluorescent area in the BLS-only-treated
mice after surgery (Fig. 4). Fluorescent-tumor areas of the mice treated with BLS-only rapidly
increased, whereas mice treated with BLS + FGS had minimal tumor recurrence (Fig. 5). Five
weeks after surgery, the fluorescent areas of BLS-only- and BLS + FGS-treated mice were 379 ±
Figure 3. Pre-operative and post-operative images of retroperitoneal fibrosarcoma. A. Pre- and post-operative images of mice in the BLS-only and
BLS + FGS groups. Upper panels are bright-field (BF), middle panels show GFP tumor fluorescence, and lower panels showmerged images. The residual
tumor after BLS-only was clearly detected with the OV100 at a magnification of 0.56×. The residual tumor after BLS + FGS was marginally detected with the
OV100. Fluorescent area of residual tumor after BLS-only and BLS + FGS. Fluorescent areas of residual tumors in BLS-only and BLS + FGS group were
10.5 ± 2.4 mm2 and 0.4 ± 0.4 mm2, respectively. The residual tumor area after BLS + FGS was significantly smaller than after BLS-only. All images were
measured for residual tumor areas using ImageJ. * p< 0.01. B. Bar graphs show the percent of the original tumor remaining after either BLS or the
combination of BLS + FGS.
doi:10.1371/journal.pone.0116865.g003
Figure 4. Representative time-course imaging of tumor recurrence after BLS-only and the combination of BLS + FGS. Fluorescence imaging, using
the iBOX Scientia Small Animal Imaging System [34, 52, 53], showed BLS-only mice treated had tumor recurrence. In contrast, mice treated with the
combination of BLS + FGS showed little recurrent tumor growth.
doi:10.1371/journal.pone.0116865.g004
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147 mm2 and 11.7 ± 6.9 mm2, respectively (Fig. 5). The combination of BLS+FGS significantly
decreased tumor recurrent more than BLS-only treated mice (p< 0.001).
Disease-free survival (DFS) after BLS and BLS + FGS
Five-week DFS rates of BLS-only- and BLS + FGS-treated mice were 9.1% and 81.8%, respec-
tively (Fig. 6). Mice treated with BLS + FGS had a significantly higher survival rate than mice
treated with BLS-only (p< 0.005). These results further suggest that FGS significantly reduced
the residual tumor volume after BLS and improved DFS.
We have previously demonstrated the enhanced visualization and resection of primary and
metastatic cancer labeled with GFP [7–16] or fluorescent antibodies [17–29]. The results of
these previous studies show the great potential of FGS. The present study demonstrates that
FGS can be beneficial for patients with retroperitoneal sarcoma to prevent recurrence of the
tumor, a major current problem in the clinic. A possible translatable method to label the fibro-
sarcoma in the clinic could be with a GFP-containing, telomerase-dependence adenovirus
which effectively and selectively labels tumors in mouse models, enabling FGS [7–9]. Another
possibility could be the use of RNA-guided nano-sensors to specifically label cancer cells in
vivo for FGS [42].
Figure 5. Extent of tumor recurrence after BLS-only or BLS+FGS. BLS-only treatedmice had tumor
recurrence. BLS + FGS-treated mice had only minimal growth of recurrent tumors. Five weeks after surgery,
the fluorescent-tumor areas of BLS-only- and BLS+FGS-treated mice were 379 ± 147 mm2 and 11.7 ± 6.9
mm2, respectively. The combination of BLS + FGS significantly decreased recurrence compared to BLS-only
treated mice. * p< 0.001.
doi:10.1371/journal.pone.0116865.g005
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